

Sanjay Kaul

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2222330/sanjay-kaul-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	15,829 citations	50 h-index	125 g-index
172 ext. papers	18,824 ext. citations	9.7 avg, IF	6.12 L-index

#	Paper	IF	Citations
144	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2021 ,	16.7	12
143	Lessons Learnt from Recent Trials in Ischemic Heart Disease. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 8-14	7	
142	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. <i>Circulation</i> , 2021 , 144, e70-e91	16.7	5
141	Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1378-1393	3.8	1
140	Should Percutaneous Coronary Intervention Be Considered for Left Main Coronary Artery Disease?: Insights From a Bayesian Reanalysis of the EXCEL Trial. <i>JAMA Internal Medicine</i> , 2020 , 180, 1002-1003	11.5	3
139	Evidence for the Universal Blood Pressure Goal of . <i>Hypertension</i> , 2020 , 76, 1391-1399	8.5	5
138	Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 985-991	15.1	7
137	Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. <i>Circulation</i> , 2020 , 142, 1974-1988	16.7	2
136	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1413-1424	59.2	1099
135	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. <i>Clinical Trials</i> , 2020 , 17, 723-728	2.2	
134	Are Guidelines for Treatment of Hypertension Trustworthy?. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3027-3030	15.1	3
133	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. <i>Circulation</i> , 2019 , 140, 379-389	16.7	14
132	Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e011318	6	30
131	Transcatheter Aortic-Valve Replacement in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019 , 381, 682	59.2	1
130	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1270-1278	12.3	73
129	Coronary Computed Tomography Angiography as the Investigation of Choice for Stable Chest Pain-Reply. <i>JAMA Cardiology</i> , 2019 , 4, 948-949	16.2	
128	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1273-1287	12.3	133

127	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019 , 21, 386-388	12.3	21
126	Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 2528-2537	5	3
125	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , 2019 , 140, 2108-2118	16.7	13
124	Evaluating the Evidence for Coronary Computed Tomography Angiography as the Noninvasive Test of Choice for Patients With Stable Chest Pain. <i>JAMA Cardiology</i> , 2019 , 4, 199-200	16.2	5
123	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
122	How Strong Is the Evidence to Support Blood Pressure Treatment Goal of 130/80 mm Hg?. <i>Circulation</i> , 2018 , 138, 2594-2596	16.7	4
121	A Deeper Dive Into the CANTOS "Responders" Substudy. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 830-833	6.4	5
120	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1661-1670	10.2	38
119	Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. <i>Diabetes Care</i> , 2017 , 40, 821-831	14.6	48
118	A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment Effects. <i>Annals of Internal Medicine</i> , 2017 , 166, 370-372	8	1
117	2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1313-1346	15.1	312
116	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
115	Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. <i>Diabetes Care</i> 2017;40:821-831. <i>Diabetes Care</i> , 2017 , 40, e175-e176	14.6	2
114	Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction. <i>JAMA Cardiology</i> , 2016 , 1, 629-30	16.2	1
113	Troponin Testing for Clinicians. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2365-2375	15.1	28
112	Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?. <i>Circulation</i> , 2016 , 134, 94-6	16.7	16
111	In Memoriam, George A. Diamond, MD 1941 to 2015. <i>American Journal of Cardiology</i> , 2016 , 117, 1192-1193		
110	The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 994-1002	8.4	20

109	Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes. <i>American Journal of Cardiology</i> , 2015 , 115, 1073-9	3	8
108	COCATS 4 Task Force 11: Training in Arrhythmia Diagnosis and Management, Cardiac Pacing, and Electrophysiology. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1854-65	15.1	17
107	Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?. <i>JAMA Internal Medicine</i> , 2015 , 175, 9-10	11.5	8
106	Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0139817	3.7	118
105	Patient selection for elective revascularization to reduce myocardial infarction and mortality: new lessons from randomized trials, coronary physiology, and statistics. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8,	3.9	27
104	Risk and the physics of clinical prediction. <i>American Journal of Cardiology</i> , 2014 , 113, 1429-35	3	31
103	Evaluation of postsurgical clinical outcomes with/without removal of pocket epithelium: A split mouth randomized trial. <i>Journal of Indian Society of Periodontology</i> , 2014 , 18, 751-61	1.1	2
102	The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. <i>New England Journal of Medicine</i> , 2013 , 369, 1285-7	59.2	138
101	On reporting of effect size in randomized clinical trials. <i>American Journal of Cardiology</i> , 2013 , 111, 613-73		6
100	The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. <i>European Heart Journal</i> , 2013 , 34, 2510-8	9.5	130
99	The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 777-81	15.1	27
98	Relationship of aspirin use with age-related macular degeneration: association or causation?: comment on "The association of aspirin use with age-related macular degeneration". <i>JAMA Internal Medicine</i> , 2013 , 173, 264-6	11.5	5
97	Subgroup analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass surgery. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2097-8	27.4	13
96	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1200-54	15.1	580
95	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular	1.5	93
94	Evidence-based use of statins for primary prevention of cardiovascular disease. <i>American Journal of Medicine</i> , 2012 , 125, 440-6, 2012 , 144, e29-84	2.4	42
93	Non-inferiority study design: lessons to be learned from cardiovascular trials. <i>European Heart Journal</i> , 2012 , 33, 1318-24	9.5	96
92	ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2427-63	15.1	278

91	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Medical Heart Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Anesthetists, Society of Thoracic Surgeons, and Society of Vascular Medicine. <i>Circulation</i> , 2012 , 125, 1288-303; discussion 1303	2.7	16
90	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. <i>Circulation</i> , 2012 , 125, 1288-303; discussion 1303	16.7	45
89	Cardiovascular risk assessment in the development of new drugs for obesity. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1099-100	27.4	10
88	Efficacy of 0.2% tempered chlorhexidine as a pre-procedural mouth rinse: A clinical study. <i>Journal of Indian Society of Periodontology</i> , 2012 , 16, 213-7	1.1	20
87	Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011 , 18, 596-603	4	22
86	Fibrates in the treatment of dyslipidemias--time for a reassessment. <i>New England Journal of Medicine</i> , 2011 , 365, 481-4	59.2	46
85	The JUPITER trial: myth or reality?. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 413-21	6	7
84	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47	16.7	2467
83	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i> , 2010 , 121, 1868-77	16.7	94
82	ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. <i>Circulation</i> , 2010 , 122, 537-57	16.7	150
81	ACCF/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures. <i>Circulation</i> , 2010 , 122, 2091-106	16.7	48
80	By Jove! What is a clinician to make of JUPITER?. <i>Archives of Internal Medicine</i> , 2010 , 170, 1073-7		40
79	Trial and error. How to avoid commonly encountered limitations of published clinical trials. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 415-27	15.1	87
78	Dronedronone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1569-76	15.1	28
77	ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1569-76	15.1	250
76	Evidence-based financial incentives for healthcare reform: putting it together. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 134-40	5.8	9
75	Cost, effectiveness, and cost-effectiveness. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 49-54	5.8	27
74	The impact of revascularization on mortality in patients with nonacute coronary artery disease. <i>American Journal of Medicine</i> , 2009 , 122, 152-61	2.4	97

73	Statins in acute coronary syndromes: do the guideline recommendations match the evidence?. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1425-33	15.1	29
72	Intravascular ultrasound tissue characterization: messages from the heart. <i>JACC: Cardiovascular Imaging</i> , 2009 , 2, 469-72	8.4	
71	Bridging therapy in the perioperative management of patients with drug-eluting stents. <i>Reviews in Cardiovascular Medicine</i> , 2009 , 10, 209-18	3.9	8
70	Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 885-92	15.1	117
69	ACC/AHA/ACCF 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1502-17	15.1	338
68	Rosiglitazone and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2008 , 10, 398-404	6	8
67	Is homocysteine a relevant cardiovascular risk factor?. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 141-149	15.1	34
66	Screen testing cardiovascular prevention in asymptomatic diabetic patients. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1915-7	15.1	34
65	As time goes by: current status and future directions in the controversy over stenting. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 128-37	15.1	40
64	COURAGE under fire: on the management of stable coronary disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1604-9	15.1	29
63	An orwellian discourse on the meaning and measurement of noninferiority. <i>American Journal of Cardiology</i> , 2007 , 99, 284-7	3	13
62	Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. <i>Progress in Cardiovascular Diseases</i> , 2007 , 49, 284-99	8.5	31
61	Current status and future trends in drug-eluting stents. <i>The American Heart Hospital Journal</i> , 2007 , 5, 165-8		1
60	Role of clopidogrel in managing atherothrombotic cardiovascular disease. <i>Annals of Internal Medicine</i> , 2007 , 146, 434-41	8	33
59	Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. <i>Annals of Internal Medicine</i> , 2007 , 147, 578-81	8	216
58	From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events. <i>American Journal of Medicine</i> , 2007 , 120, 5-11	2.4	15
57	Cardiac amyloidosis: new insights into diagnosis and management. <i>Reviews in Cardiovascular Medicine</i> , 2007 , 8, 189-99	3.9	8
56	Harold James Charles (Jeremy) Swan, MD, PhD. <i>American Journal of Cardiology</i> , 2006 , 97, 1545-1546	3	2

55	Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 914-23	15.1	119
54	Good enough: a primer on the analysis and interpretation of noninferiority trials. <i>Annals of Internal Medicine</i> , 2006 , 145, 62-9	8	178
53	Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. <i>Annals of Internal Medicine</i> , 2006 , 144, 913-9	8	84
52	Trials and tribulations of non-inferiority: the ximelagatran experience. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1986-95	15.1	85
51	ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005 , 5, 471-9		9
50	Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. <i>Circulation</i> , 2004 , 110, 1701-5	16.7	125
49	Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible NO synthase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 1652-8	9.4	35
48	Efficiency versus cost of alternative fuels from renewable resources: outlining decision parameters. <i>Energy Policy</i> , 2004 , 32, 929-935	7.2	11
47	Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1929-39	15.1	83
46	Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1311-9	15.1	65
45	Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 41, 615-24	3.1	10
44	Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. <i>Thrombosis Research</i> , 2003 , 112, 99-104	8.2	6
43	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. <i>Circulation</i> , 2003 , 108, 1664-72	16.7	1985
42	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. <i>Circulation</i> , 2003 , 108, 1772-8	16.7	886
41	A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003 , 8, 193-200	2.6	12
40	Intramural delivery of recombinant apolipoprotein A-I-Milano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. <i>Circulation</i> , 2003 , 107, 2551-4	16.7	69
39	Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. <i>Circulation</i> , 2002 , 105, 1970-5	16.7	41
38	Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. <i>Atherosclerosis</i> , 2002 , 161, 35-43	3.1	12

37	Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. <i>Circulation</i> , 2001 , 104, 2376-83	16.7	211
36	Primary angioplasty for acute myocardial infarction in octogenarians. <i>American Journal of Cardiology</i> , 2001 , 88, 680-3	3	8
35	Intravenous magnesium in experimental stent thrombosis in swine. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 21, 1544-9	9.4	27
34	High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. <i>Circulation</i> , 2001 , 103, 3047-50	16.7	331
33	Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. <i>Circulation</i> , 2001 , 104, 3103-8	16.7	535
32	Humankind's detour toward sustainability: past, present, and future of renewable energies and electric power generation. <i>Renewable and Sustainable Energy Reviews</i> , 2000 , 4, 295-313	16.2	30
31	Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute myocardial infarction. <i>Circulation</i> , 2000 , 102, 1611-6	16.7	72
30	Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. <i>American Heart Journal</i> , 2000 , 140, 212-8	4.9	42
29	Metastatic pancreatic adenocarcinoma to the heart diagnosed antemortem. <i>Journal of the American Society of Echocardiography</i> , 2000 , 13, 415-6	5.8	3
28	Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1699-712	15.1	63
27	The aggressive low density lipoprotein lowering controversy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1419-25	15.1	18
26	Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 493-501	15.1	64
25	Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 300-7	15.1	109
24	Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. <i>Circulation</i> , 1999 , 99, 1284-9	16.7	125
23	Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. <i>Circulation Research</i> , 1999 , 85, 1192-8	15.7	96
22	Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. <i>Circulation</i> , 1999 , 99, 168-77	16.7	260
21	Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. <i>Circulation</i> , 1999 , 99, 3103-9	16.7	236
20	Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. <i>Circulation</i> , 1999 , 99, 993-8	16.7	237

19	Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 1999 , 84, 152-6	3	81
18	Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. <i>American Journal of Cardiology</i> , 1999 , 84, 1011-7	3	119
17	ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 273-82	15.1	336
16	Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998 , 115, 604-12; discussion 612-4	1.5	63
15	Variation in use of invasive procedures in acute ischemic syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 1998 , 2, 113-4		
14	Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , 1998 , 97, 780-5	16.7	219
13	Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1998 , 3, 91-102	2.6	3
12	Local Delivery of an Ultra-short-acting Nitric Oxide-releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1997 , 2, 181-194	2.6	3
11	Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. <i>Circulation</i> , 1997 , 95, 1015-21	16.7	26
10	Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. <i>Circulation</i> , 1996 , 94, 2228-34	16.7	16
9	Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 134-41	3.1	17
8	Price elasticity of petroleum products in selected African countries. <i>Energy Conversion and Management</i> , 1995 , 36, 219-224	10.6	1
7	Role of platelets and leukocytes in modulation of vascular tone. <i>Annals of the New York Academy of Sciences</i> , 1994 , 714, 122-35	6.5	11
6	Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. <i>American Journal of Cardiology</i> , 1993 , 72, 1352-6	3	32
5	Traumatic mitral insufficiency complicating blunt chest trauma treated medically: a case report and review. <i>Critical Care Medicine</i> , 1992 , 20, 1064-8	1.4	20
4	Rural household energy use in China. <i>Energy</i> , 1992 , 17, 405-411	7.9	15
3	Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. <i>American Heart Journal</i> , 1991 , 122, 535-44	4.9	117
2	Honeycomb roof cover system for passive solar space heating. <i>Energy Conversion and Management</i> , 1987 , 27, 99-102	10.6	7

1 Homocysteine and Cardiovascular Disease413-439